2 results
Approved WMOCompleted
The primary objective is to assess the clinical efficacy of siltuximab (a chimeric (murine-human) IgG1* mAb that specifically binds human IL-6 with high affinity and prevents its interaction with the IL-6 receptor, glycoprotein (GP) 80),…
Approved WMOCompleted
To investigate whether discontinuation of Syntocinon® infusion after the onset of active labour decreases caesarean section rates compared to usual care; continuation of oxytocin until the baby and placenta is born.